Cardio Flow

Cardio Flow is a commercial-stage medical device company focused on improving treatment for peripheral artery disease (PAD) through its innovative FreedomFlow Orbital Atherectomy Platform. The platform features a unique helical driveshaft with diamond-coated spheres, leveraging angular momentum to debulk plaque in vessels from 2mm to 8mm in diameter. With two clinical trials (FAST I and FAST II) completed and real-world evidence gathered, the company is positioned in the competitive atherectomy market, emphasizing procedural efficiency, a low learning curve, and reduced capital costs for healthcare providers. Its commercial strategy targets hospitals, ambulatory surgery centers, and office-based labs.

The FreedomFlow Orbital Atherectomy Platform: a catheter-based system using a helical driveshaft with diamond-coated spheres. The off-axis rotation creates angular momentum for plaque removal in vessels 2mm-8mm in diameter. The platform integrates the motor and saline pump into a single-use catheter for ease of use and low capital cost.

The peripheral atherectomy market is competitive and dominated by large players like Boston Scientific, Philips, and Medtronic. Cardio Flow differentiates by offering an integrated, low-capital-cost platform designed for procedural efficiency and flexibility across vessel sizes, targeting cost-sensitive settings like ASCs.